I-Euflexxa Injections Isetyenziswe kwi-Viscosupplementation
U-Euflexxa isisombululo se hyaluronan ehlambulukileyo (ebizwa ngokuba yi-hyaluronic acid okanye i-hyaluronate ye-sodium) kwi-saline. I-hyaluronan e-Euflexxa ikhutshwa kwiiseli zebhaktheriya. Yona yokuqala ye-hyaluronan engekho ye-avian.
U-Euflexxa ungenye ye-hyaluronates esetyenziswa kwi- viscosupplementation . I-Euflexxa ijojowe ngqo kwixolo elihlangeneyo ukuze kubuyiselwe iipropati zokugcoba kunye nokuhlanjululwa kwe- synovial fluid ejwayelekile (oko kukuthi, umbane ohlangeneyo).
Amalungu amaninzi athatyathelwe yi-osteoarthritis alahlekelwa yimpahla yazo.
Isibonakaliso se-Euflexxa
I-Euflexxa yavunywa yi-US FDA ngomhla kaDisemba 3, 2004 ukunyangwa kweentlungu zamadolo ezinxulumene ne- osteoarthritis kwizigulane eziye zahluleka ukuphendula kwindlela yokwelapha engapheliyo yonyango (umz., Unyango lomzimba) kunye nama-analgesics alula, njenge- acetaminophen . I-Euflexxa ilawulwa njengengxube yeeyilisi ezintathu ze- intra-articular zeveki nganye.
Ukungqinelana kweEuflexxa
Abantu abane-hypersensitivity eyaziwayo kwiimveliso ze-hyaluronan akufanele baphathwe nge-Euflexxa. Kwakhona, abantu abanentsholongwane emadolweni, omnye usulelo, okanye isifo esikhwameni apho umjovo oza kwenzeka khona akufanele unyangwe nge-Euflexxa.
Iimpawu eziqhelekileyo kunye neziganeko ezimbi
Iziganeko eziqhelekileyo eziqhelekileyo ezinxulumene nophando lwe-Euflexxa ngexesha lophando lwezonyango ziquka i-arthralgia (intlungu edibeneyo), intlungu emva, intlungu kwiingalo okanye emilenzeni, intlungu ye-musculoskeletal, kunye nokuvuvukala okuhlangeneyo.
Iziganeko ezimbi ezinokuthi zenzeke nazo nayiphi na injini ye-intra-articular zibandakanya i-arthralgia, ukuvuvukala okuhlangeneyo, ukuxhamla okuhlangeneyo, intlungu yesifo kunye ne-arthritis.
Ukuqapha kunye nezilumkiso
Emva kokufumana i-injection intra-articular ye-Euflexxa, njengawo nawuphi na umjovo ojoyiweyo, kuyacetyiswa ukuba isiguli sigweme imisebenzi enzima okanye imisebenzi yokunyamezela ixesha elide malunga neeyure ezingama-48.
Kwakhona, ku funeka kuqatshelwe ukuba intlungu okanye ukuvuvukala kwenzeka emva kokujova, kodwa kuya kuncipha emva kwexesha elifutshane.
Ukhuseleko kunye nokusebenza kwe-Euflexxa akuzange kusekwe kwabasetyhini abakhulelweyo. Ayaziwa ukuba i-Euflexxa idityaniswe ebisi loluntu njengoko ukhuseleko kunye nokusebenza akuzange kusungulwe kubasetyhini abahlaselayo. Kwakhona, ukhuseleko kunye nokusebenza kwe-Euflexxa ayinakusungulwa kubantwana.
Ngaphantsi
Ezinye ii-viscosupplements ezivunyiweyo ze-FDA, kunye nomhla abavunyelweyo, zibandakanya:
- Hyalgan 05/28/1997
- ISixvisc 08/08/1997
- Supartz 01/24/2001
- IOrthovisc 02/05/2004
I-American Association of Orthopedic Surgeons (AAOS) yagqiba, "Nangona ezinye izigulane zibika uxolo lweempawu ze-arthritis nge-viscosupplementation, le nkqubo ayizange iboniswe ukuba iguqule inkqubo ye-arthritic okanye ibuye ikhule kwakhona i-cartilage.Ukusebenza kakuhle kwe-viscosupplementation ekwenzeni i-arthritis akucaci Kuye kucetyiswa ukuba i-viscosupplementation iphumelele kakhulu xa i-arthritis isemagqabini ayo okuqala (okuncinci ukuya ekumodareyithini), kodwa uphando olongezelelweyo lufunekayo ukuxhasa le nto.Uphando kwi-viscosupplementation kunye nemiphumo yakhe yesikhathi eside iqhubeka. "
> Imithombo:
> I-Viscosupplementation Treatment for Knee Arthritis. I-OrthoInfo (AAOS). Ukuhlaziywa ngoJuni 2015.
> Euflexxa. Ulwaziso loLwazi. Julayi 2017
> I-Ferring Pharmaceuticals Izisa ukuqaliswa kwe-Euflexxa Kwi-Osteoarthritis Knee Pain, i-News Release Ferring Pharmaceuticals Inc., ngoNovemba 14, 2005.